Advice

In the absence of a submission from the holder of the marketing authorisation

Teriparatide (Forsteo) is not recommended for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice50KB (PDF)

Download

Medicine details

Medicine name:
teriparatide 20 micrograms/80 microlitres, solution for injection, in prefilled pen (Forsteo)
SMC ID:
487/08
Indication:
for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Endocrine system
Submission type
Non submission
Status
Not recommended
Date advice published:
09 June 2008